SG11202012835RA - Modifying binding molecules to minimize pre-existing interactions - Google Patents

Modifying binding molecules to minimize pre-existing interactions

Info

Publication number
SG11202012835RA
SG11202012835RA SG11202012835RA SG11202012835RA SG11202012835RA SG 11202012835R A SG11202012835R A SG 11202012835RA SG 11202012835R A SG11202012835R A SG 11202012835RA SG 11202012835R A SG11202012835R A SG 11202012835RA SG 11202012835R A SG11202012835R A SG 11202012835RA
Authority
SG
Singapore
Prior art keywords
binding molecules
minimize pre
modifying binding
existing interactions
interactions
Prior art date
Application number
SG11202012835RA
Inventor
Giane Sumner
Jihua Chen
Michael Partridge
Albert Torri
Manoj Rajadhyaksha
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202012835RA publication Critical patent/SG11202012835RA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11202012835RA 2018-07-10 2019-07-10 Modifying binding molecules to minimize pre-existing interactions SG11202012835RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695988P 2018-07-10 2018-07-10
PCT/US2019/041203 WO2020014358A1 (en) 2018-07-10 2019-07-10 Modifying binding molecules to minimize pre-existing interactions

Publications (1)

Publication Number Publication Date
SG11202012835RA true SG11202012835RA (en) 2021-01-28

Family

ID=67544330

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012835RA SG11202012835RA (en) 2018-07-10 2019-07-10 Modifying binding molecules to minimize pre-existing interactions

Country Status (13)

Country Link
US (2) US11448651B2 (en)
EP (1) EP3820891A1 (en)
JP (1) JP2021531245A (en)
KR (1) KR20210030378A (en)
AR (1) AR115730A1 (en)
AU (1) AU2019302642A1 (en)
BR (1) BR112020026784A2 (en)
CA (1) CA3104873A1 (en)
EA (1) EA202190228A1 (en)
IL (1) IL279803A (en)
MX (1) MX2021000239A (en)
SG (1) SG11202012835RA (en)
WO (1) WO2020014358A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190228A1 (en) 2018-07-10 2021-04-14 Ридженерон Фармасьютикалз, Инк. MODIFICATION OF BINDING MOLECULES TO MINIMIZE PRE-EXISTING INTERACTIONS

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1822857A (en) * 2003-06-02 2006-08-23 阿莱克申药物公司 De-immunized anti-CD3 antibody
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
JP4294082B2 (en) 2006-03-23 2009-07-08 協和発酵キリン株式会社 Agonist antibody to human thrombopoietin receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2712021A1 (en) 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Methods and kits for detecting antibodies against therapeutic antibodies
SG172754A1 (en) * 2008-10-10 2011-08-29 Trubion Pharmaceuticals Inc Tcr complex immunotherapeutics
US20110212849A1 (en) 2008-10-24 2011-09-01 Vereniging VU-Windesheim; Vereniging voor Christelijk Hoger Onderwijs, Biomarkers for predicting the development of chronic autoimmune diseases
DE102008061522A1 (en) 2008-12-10 2010-06-17 Biontech Ag Use of Flt3 ligand to enhance immune responses in RNA immunization
WO2010122148A1 (en) * 2009-04-24 2010-10-28 Boehringer Ingelheim International Gmbh An improved antibody domain and antibody fragments and antibodies based thereon
WO2011074965A1 (en) 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
JP2014518632A (en) 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン Chemokine-immunoglobulin fusion polypeptides, compositions, methods of making and using the same
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
JP6623353B2 (en) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー Anti-PD-1 antibodies and their use for therapy and diagnosis
EP3736575A1 (en) * 2014-11-05 2020-11-11 F. Hoffmann-La Roche AG Method for the determination of anti-drug antibodies against an effector function suppressed human or humanized drug antibody
CN107206073A (en) * 2014-11-14 2017-09-26 赛诺菲生物技术公司 By applying the method that IL 4R antagonists are used to treat the chronic nasosinusitis with nasal polyp
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
CN114891102A (en) 2015-10-29 2022-08-12 豪夫迈·罗氏有限公司 Anti-variant Fc region antibodies and methods of use
WO2018053405A1 (en) * 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 Anti-hla-g antibodies and use thereof
EP3713966A1 (en) 2017-11-22 2020-09-30 Vacara AB Antibodies to citrullinated proteins
EA202190228A1 (en) 2018-07-10 2021-04-14 Ридженерон Фармасьютикалз, Инк. MODIFICATION OF BINDING MOLECULES TO MINIMIZE PRE-EXISTING INTERACTIONS
WO2020246891A1 (en) 2019-06-07 2020-12-10 Sanquin Innovatie B.V. Methods and compounds for typing rheumatoid factors

Also Published As

Publication number Publication date
EP3820891A1 (en) 2021-05-19
MX2021000239A (en) 2021-03-25
US11448651B2 (en) 2022-09-20
IL279803A (en) 2021-03-01
KR20210030378A (en) 2021-03-17
JP2021531245A (en) 2021-11-18
EA202190228A1 (en) 2021-04-14
TW202021984A (en) 2020-06-16
BR112020026784A2 (en) 2021-03-30
CN112543768A (en) 2021-03-23
WO2020014358A1 (en) 2020-01-16
US20200018754A1 (en) 2020-01-16
US20230266333A1 (en) 2023-08-24
AR115730A1 (en) 2021-02-17
AU2019302642A1 (en) 2021-02-25
CA3104873A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL273631A (en) Hpv-specific binding molecules
IL276537A (en) Antibodies binding to gprc5d
IL275510A (en) Ror1-specific antigen binding molecules
HK1254966A1 (en) Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
IL281901A (en) Multivalent igm- and iga-fc-based binding molecules
HK1252856A1 (en) Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
HK1254068A1 (en) Bispecific t cell activating antigen binding molecules
HK1255107A1 (en) Antigen binding constructs to target molecules
LT3177646T (en) Cd3 binding domain
EP3352760A4 (en) Cd3 binding polypeptides
GB201612520D0 (en) Binding molecules
GB201702091D0 (en) Specific binding molecules
PL3166970T3 (en) Improved a-beta protofibril binding antibodies
GB201811410D0 (en) OX40 Binding molecules
IL269394A (en) Antibodies binding to steap-1
IL287555A (en) Binding molecules
GB201811408D0 (en) CD137 Binding Molecules
GB201901305D0 (en) Specific binding molecules
IL279803A (en) Modifying binding molecules to minimize pre-existing interactions
EP3243837A4 (en) Bispecific antibody binding to trailr2 and psma
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201915282D0 (en) Specific binding molecules
GB201914468D0 (en) Binding Molecules